Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: A pilot randomized trial in head and neck cancer

Oral Oncology

Volumn 48, Issue 11, 2012, Pages 1136-1145

  Moskowitz, Howard S ^a   Gooding, William E ^b   Thomas, Sufi M ^c   Freilino, Maria L ^c   Gross, Neil ^d   Argiris, Athanassios ^e   Grandis, Jennifer R ^c   Ferris, Robert L ^b,c  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

Biomarkers; COX; EGFR; Erlotinib; HNSCC; Sulindac

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 6; PROSTAGLANDIN SYNTHASE; SULINDAC;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK CANCER; HUMAN; MALE; MODULATION; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SERUM; SIGNAL TRANSDUCTION; VALIDATION STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK NEOPLASMS; HEPATOCYTE GROWTH FACTOR; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PILOT PROJECTS; PLACEBOS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SULINDAC; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR MARKERS, BIOLOGICAL;

EID: 84867858789     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2012.05.015     Document Type: Article

References (29)

1. A. Argiris, M.V. Karamouzis, D. Raben, and R.L. Ferris Head and neck cancer Lancet 371 9625 2008 1695 1709
2. J.D. Moyer, E.G. Barbacci, K.K. Iwata, L. Arnold, B. Boman, and A. Cunningham Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase Cancer Res 57 21 1997 4838 4848
3. R. Perez-Soler, A. Chachoua, L.A. Hammond, E.K. Rowinsky, M. Huberman, and D. Karp Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 16 2004 3238 3247
4. A.N. Gordon, N. Finkler, R.P. Edwards, A.A. Garcia, M. Crozier, and D.H. Irwin Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study Int J Gynecol Cancer 15 5 2005 785 792
5. D. Soulieres, N.N. Senzer, E.E. Vokes, M. Hidalgo, S.S. Agarwala, and U. Siu Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck J Clin Oncol 22 1 2004 77 85
6. S.M. Thomas, N.E. Bhola, Q. Zhang, S.C. Contrucci, A.L. Wentzel, and M.L. Frelino Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma Cancer Res 66 24 2006 11831 11839
7. L.J. Wirth, R.I. Haddad, N.I. Lindeman, X. Zhao, J.C. Lee, and V.A. Joshi Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck J Clin Oncol 23 28 2005 6976 6981
8. Z. Chen, X. Zhang, M. Li, Z. Wang, H.S. Wieand, and J.R. Grandis Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck Clin Cancer Res 10 17 2004 5930 5939
9. F. Linkov, A. Lisovich, Z. Yurkovetsky, A. Marrangoni, L. Velikokhatnaya, and B. Nolen Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling Cancer Epidemiol Biomar Prev 16 1 2007 102 107
10. C.H. Chung, E.H. Seeley, H. Roder, J. Grigorieva, M. Tsypin, and J. Roder Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients Cancer Epidemiol Biomar Prev 19 2 2010 358 365
11. B. Hathaway, D.P. Landsittel, W. Gooding, T.L. Whiteside, J.R. Grandis, and J. Siegfried Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients Laryngoscope 115 3 2005 522 527
12. F. Linkov, R.L. Ferris, Z. Yurkovetsky, A. Marrangoni, L. Velikokhatnaya, and W. Gooding Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases Proteomics Clin Appl 2 12 2008 1575 1585
13. J. Storey, and R. Tibshirani Statistical significance of genomewide studies Proc Natl Acad Sci USA 100 16 2003 9440 9445 [Epub 2003, July 25]
14. Y. Hochberg, and Y. Benjamini More powerful procedures for multiple significance testing Stat Med 9 7 1990 811 818
15. J. Wang, R.R. Seethala, Q. Zhang, W. Gooding, C. van Waes, and H. Hasegawa Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: implications for therapy J Natl Cancer Inst 100 7 2008 502 512
16. S. Zhou, S. Ren, L. Yan, L. Zhang, and L. Tang Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer Respirology 14 5 2009 709 715
17. F. Meyer, E. Samson, P. Douville, T. Duchesne, and G. Liu Serum prognostic markers in head and neck cancer Clin Cancer Res 16 3 2010 1008 1015
18. C. Allen, S. Duffy, T. Teknos, M. Islam, Z. Chen, and P.S. Albert Nuclear factor-{kappa}B-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma Clin Cancer Res 13 11 2007 3182 3190
19. A.T. Baron, J.A. Wilken, D.E. Haggstrom, S.T. Goodrich, and N.J. Maihle Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer IDrugs 12 5 2009 302 308
20. A. Egloff, T.M. Feinstein, S.C. Joyce, L.A. Kelly, M.C. Panelli, and T. Yang Blood biomarker modulation with dasatinib and cetuximab in patients with advanced solid malignancies J Clin Oncol 27 15 Suppl 2009 [abstr 6034]
21. D.M. Hickinson, G.B. Marshall, G.J. Beran, M. Varella-Garcia, E.A. Mills, and M.C. South Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib Clin Trans Sci 2 3 2009 183 192
22. F.G. Pernas, C.T. Allen, M.E. Winters, B. Yan, J. Friedman, and B. Dabir Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer Clin Cancer Res 15 7 2009 2361 2372
23. M. Agulnik, G. da Cunha Santos, D. Hedley, T. Nicklee, P.P. Dos Reis, and J. Ho Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib J Clin Oncol 25 6 2007 2184 2190
24. E. Calvo, S.N. Malik, L.L. Siu, G.M. Baillargeon, J. Irish, and S.F. Chin Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer Ann Oncol 18 4 2007 761 767
25. F. Thomas, P. Rochaix, A. Benlyazid, J. Sarini, M. Rives, and J.L. Lefebvre Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma Clin Cancer Res 13 23 2007 7086 7092
26. G.E. Lash, P.J. Scaife, B.A. Innes, H.A. Otun, S.C. Robson, and R.F. Searle Comparison of three multiplex cytokine analysis systems: Luminex, SearchLight and FAST Quant J Immunol Methods 309 1-2 2006 205 208
27. G. Toedter, K. Hayden, C. Wagner, and C. Brodmerkel Simultaneous detection of eight analytes in human serum by two commercially available platforms for multiplex cytokine analysis Clin Vaccine Immunol 15 1 2008 42 48
28. I.H. Khan, V.V. Krishnan, M. Ziman, K. Janatpour, T. Wun, and P.A. Luciw A comparison of multiplex suspension array large-panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients Cytometry B Clin Cytom 76 3 2009 159 168
29. A.C. Backen, J. Cummings, C. Mitchell, G. Jayson, T.H. Ward, and C. Dive 'Fit-for-purpose' validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use J Immunol Methods 342 1-2 2009 106 114